US Patent 8,492,441: Scope, Claims, Expiration and S1P Agonist Patent Landscape
US Patent 8,492,441 protects dose-escalation methods for S1P receptor agonists, principally fingolimod-based treatment protocols for multiple sclerosis. The patent does not claim fingolimod as a chemical compound. Its commercial value lies in methods designed to reduce the initial negative chronotropic effect associated with S1P receptor modulation by starting treatment below the maintenance dose and increasing the dose over an initial treatment period.
The patent was assigned to Novartis AG. Its claims focus on three linked concepts:
- Initial administration below the standard daily dose.
- Stepwise escalation to the standard therapeutic dose.
- Use of the protocol to reduce or prevent treatment-related heart-rate slowing.
The principal commercial product implicated by the claims is Gilenya, whose active ingredient is fingolimod hydrochloride.
What does US Patent 8,492,441 claim?
The independent claims are method-of-treatment claims.
| Claim |
Core subject matter |
Commercial relevance |
| 1 |
Administering an S1P agonist below the standard daily dose initially, then increasing to the standard dose |
Broad dose-escalation claim |
| 9 |
Treating with an S1P agonist that causes a negative chronotropic effect using an initial lower dose |
Cardiac safety-focused method |
| 13 |
Ameliorating or preventing negative chronotropic side effects through lower initial dosing and escalation |
Side-effect-management claim |
Claims 2, 3, 10 and 11 narrow the treatment to autoimmune disease and, specifically, multiple sclerosis.
Claims 5, 12 and 14 narrow the S1P agonist to Compound A or an acceptable salt or prodrug. In the commercial context of Gilenya, Compound A is understood to correspond to fingolimod, also known as FTY720, administered commercially as fingolimod hydrochloride.
Claims 6 through 8 and 15 through 16 add dosing details:
- The initial dose may be 80-fold, 40-fold, 10-fold or fourfold below the standard dose.
- The dose may be increased stepwise.
- The dose administered on a particular day may approximate the sum of the doses given during the prior two days, within a range of plus or minus 40%.
- The lower-dose period may cover the first 10 days.
How broad is the main claim?
Claim 1 is materially broader than the fingolimod-specific dependent claims.
It covers a method involving:
- Any subject in need of treatment.
- A medication containing an S1P receptor agonist or modulator.
- An initial dose below the standard daily dosage.
- A subsequent increase up to the standard daily dosage.
The claim does not expressly limit the treatment to multiple sclerosis, autoimmune disease, fingolimod, a particular dosage form or a particular escalation schedule.
That breadth creates several claim-construction issues.
What does “standard daily dosage” mean?
The phrase is central to infringement analysis. For fingolimod, the commercial maintenance dose for adults is generally 0.5 mg once daily. The claim compares the initial dose against the standard daily dose of the particular S1P agonist being administered.
A generic manufacturer could dispute whether “standard daily dosage” means:
- The FDA-approved maintenance dose.
- The dose used in the innovator label.
- The usual clinical dose at the relevant filing date.
- A dose established by clinical practice or prescribing information.
For fingolimod, the FDA-approved adult maintenance dose provides the clearest benchmark. For other S1P agonists, the term may be more difficult to apply because the approved dose, target population and titration requirements can differ.
What does “initial period of treatment” mean?
Claims 1 and 9 do not specify a fixed number of days. Claims 15 and 16 introduce a 10-day period, but those claims are narrower.
A protocol can therefore fall within claim 1 even if the initial period lasts fewer or more than 10 days, provided the other claim elements are met. The absence of a fixed duration increases potential scope but also creates vulnerability to indefiniteness, written-description and enablement arguments.
Does the claim require a cardiac event?
Claims 1 and 9 differ in this respect.
Claim 1 requires an S1P agonist and dose escalation but does not expressly require that the patient experience bradycardia or another cardiac event.
Claim 9 requires an S1P agonist “which induces a negative chronotropic effect in heart rate.” The treatment objective is not necessarily that the patient actually experience a measurable heart-rate reduction. The relevant question is whether the administered agent has the claimed pharmacologic property.
Claim 13 is narrower in purpose because it requires a method of ameliorating or preventing the negative chronotropic side effect associated with S1P agonist treatment.
What compounds are covered by the chemical genus in claim 4?
Claim 4 incorporates a highly complex chemical genus defined by formulas Ia and Ib. The genus includes compounds having variable:
- Acidic or phosphate-like substituents.
- Aryl or heteroaryl groups.
- Alkylene or alkenylene linkers.
- Heteroatoms including oxygen, sulfur and nitrogen.
- Alkyl, haloalkyl, alkoxy and aryl substituents.
- N-oxide, prodrug, salt, solvate and hydrate forms.
Claim 4 is not limited to fingolimod. It attempts to capture a broader family of S1P receptor agonists that satisfy the specified structural variables. Claim 5 then narrows the method to Compound A.
From an infringement perspective, claim 4 requires a structural comparison against the claimed Markush variables. A product may avoid claim 4 while remaining within claim 1 if it is an S1P agonist administered through the claimed dose-escalation method.
What is the relationship between claims 1, 9 and 13?
| Issue |
Claim 1 |
Claim 9 |
Claim 13 |
| S1P agonist required |
Yes |
Yes |
Yes |
| Initial dose below standard dose |
Yes |
Yes |
Yes |
| Escalation to standard dose |
Yes |
Yes |
Yes |
| Negative chronotropic effect required |
No express requirement |
Yes |
Yes, as the side effect being addressed |
| Autoimmune disease |
Only in dependent claim 2 |
Dependent claim 10 |
Expressly included |
| Multiple sclerosis |
Dependent claim 3 |
Dependent claim 11 |
Not expressly required in claim 13 |
| Stepwise increase |
Not in claim 1, added in claim 7 |
Not required by claim 9 |
Required by claim 13 |
| First 10 days |
Claim 15 |
Not in claim 9 |
Claim 16 |
The claims are drafted with overlapping coverage. A product label or physician-directed regimen may implicate multiple claims simultaneously. Claims 1 and 9 provide the broadest independent-method coverage, while claims 7, 8, 13, 15 and 16 provide more specific fallback positions.
What patent protects fingolimod dose escalation?
US Patent 8,492,441 is a regimen patent associated with fingolimod dose initiation and escalation. It is distinct from patents claiming:
- Fingolimod itself.
- Fingolimod salts.
- Methods of treating multiple sclerosis with fingolimod.
- Pharmaceutical compositions containing fingolimod.
- Manufacturing processes for fingolimod.
- Specific clinical monitoring procedures.
The patent therefore sits within a layered Gilenya estate.
| Patent category |
Protection target |
Relevance to generic entry |
| Compound patent |
Fingolimod chemical structure |
Historically primary barrier; generally expired before the regimen patents |
| Salt or formulation patent |
Fingolimod hydrochloride or dosage form |
May affect product design and labeling |
| Method-of-use patent |
Multiple sclerosis treatment |
Can support a label-based infringement theory |
| Dose-escalation patent |
Initial low-dose titration |
Relevant to prescribing instructions and generic labeling |
| Manufacturing patent |
Synthesis or purification |
Relevant to API sourcing |
| Regulatory exclusivity |
FDA approval rights |
Separate from patent term |
When does US Patent 8,492,441 expire?
The patent claims priority to a December 17, 2004 filing date. The ordinary US patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and terminal-disclaimer rules. On that basis, the unadjusted projected expiration date is December 17, 2024.
The operative expiration date must be determined from the USPTO patent-term calculation and any applicable regulatory extension. The patent grant date, July 23, 2013, does not independently determine the expiration date. A patent-term adjustment could move the expiration beyond the nominal 20-year date, while a terminal disclaimer or other limitation could shorten it. The USPTO patent record is the controlling source for the enforceable term.[1]
The patent’s commercial significance therefore depends heavily on:
- The actual USPTO-adjusted expiration date.
- Whether the patent was listed for the relevant FDA product.
- Whether a generic applicant challenged the patent before expiration.
- Whether the generic label reproduced the patented titration method.
- Whether a court adopted a broad or narrow construction of “standard daily dosage.”
What is the Orange Book status of US Patent 8,492,441?
The FDA Orange Book separates listed patents into categories such as drug-substance, drug-product and method-of-use patents. A method-of-use patent can be listed only if it claims an approved use reflected in the product labeling and satisfies FDA listing requirements.[2]
For Gilenya, the relevant regulatory question is not merely whether US Patent 8,492,441 exists. The questions are:
- Whether Novartis listed the patent against Gilenya.
- Which use code was assigned.
- Whether the approved label included the claimed initiation regimen.
- Whether the listing remained active when abbreviated new drug applications were filed.
- Whether an applicant submitted a Paragraph IV certification.
A method patent can create an ANDA litigation pathway even though it does not claim the active ingredient. If the generic applicant certifies that the listed method patent is invalid, unenforceable or not infringed, the patent holder may have 45 days to file suit, potentially triggering a 30-month stay under Hatch-Waxman.[3]
Which companies challenged fingolimod exclusivity?
Generic fingolimod development has involved multiple ANDA applicants after expiration or narrowing of the core Gilenya exclusivity barriers. Publicly reported generic competition has included products from manufacturers such as:
- HEC Pharm Co.
- Torrent Pharmaceuticals.
- Dr. Reddy’s Laboratories.
- Zydus Pharmaceuticals.
- Mylan or Viatris-related entities.
- Cipla and other international suppliers, depending on market and approval status.
The existence of an ANDA or market launch does not establish that a particular applicant infringed US Patent 8,492,441. The relevant analysis requires applicant-specific review of:
- The Paragraph IV certification.
- The proposed label.
- The ANDA product strength and dosage form.
- The treatment indication.
- Any settlement agreement.
- Any consent judgment or covenant not to sue.
What generic launch risks arise from the patent?
Label-based infringement risk
The strongest risk arises if the generic label instructs patients to begin fingolimod below 0.5 mg and escalate to 0.5 mg. Such labeling could read directly on claims 1, 7, 9, 13, 15 or 16.
Carve-out risk
A generic applicant may attempt a section viii label carve-out for the patented method. That strategy is difficult if the initial-dose regimen is embedded in the FDA-approved labeling or is necessary for safe administration.
Physician-use risk
Even if the generic label omits the patented regimen, physicians may independently prescribe a titration schedule. That creates a possible induced-infringement issue, although liability would depend on the evidence of active encouragement and the scope of the final label.
Design-around risk
A manufacturer could seek to avoid the patent by:
- Using a full maintenance dose from the outset, if medically and regulatorily acceptable.
- Using a different initiation schedule.
- Omitting a titration instruction from the label.
- Relying on a different S1P agonist outside the claim 4 genus.
- Developing a product for a noncovered indication.
These approaches may create regulatory or clinical disadvantages. A safe label cannot always be designed independently of the innovator’s approved initiation protocol.
How strong is the patent estate?
The estate is strongest against a fingolimod generic that reproduces the approved Gilenya initiation procedure. Its strongest features are:
- Broad independent method claims.
- Multiple overlapping claims.
- Specific coverage for negative chronotropic effects.
- Fingolimod-focused dependent claims.
- Claims directed to both general titration and a 10-day escalation period.
Its principal weaknesses are:
- The claims do not cover fingolimod itself.
- “Standard daily dosage” may invite claim-construction disputes.
- “Initial period” is not fixed in the broad claims.
- The stepwise mathematical limitation in claim 8 may be difficult to prove from real-world prescribing records.
- Patent expiration materially limits future enforcement value.
- A generic may challenge validity based on obviousness, written description, enablement or indefiniteness.
Prior-art analysis would likely focus on earlier S1P agonist studies, dose-escalation protocols, cardiac monitoring practices and publications describing first-dose bradycardia. The central obviousness question would be whether a skilled artisan would have been motivated to initiate treatment below the maintenance dose and increase it to reduce the known negative chronotropic effect.
What licensing and settlement issues matter?
A settlement concerning another Gilenya patent does not automatically resolve US Patent 8,492,441. The agreement must be reviewed for:
- Patent-by-patent coverage.
- Licensed entry date.
- Authorized strengths and formulations.
- Authorized indications.
- Restrictions on launch before patent expiration.
- Acceleration clauses.
- Covenants not to sue.
- Worldwide versus US-only rights.
Licensees may enter the market before the nominal patent expiration date if the patent holder grants rights or settles litigation. Conversely, an ANDA approval does not guarantee freedom to launch if a separate method patent remains enforceable.
Key Takeaways
- US Patent 8,492,441 is a dose-escalation and cardiac-safety patent, not a fingolimod compound patent.
- Claim 1 broadly covers starting an S1P agonist below its standard daily dose and increasing it to the standard dose.
- Claims 9 and 13 focus more directly on negative chronotropic effects.
- Claims 5, 12 and 14 narrow the scope to Compound A, understood in the Gilenya context as fingolimod or an acceptable form.
- Claims 15 and 16 address a lower-dose period covering the first 10 days.
- The key infringement variables are the generic label, the definition of standard daily dosage and the initial titration schedule.
- The nominal 20-year term runs from the December 17, 2004 priority date, subject to USPTO term adjustments and other statutory modifications.
- Orange Book listing, Paragraph IV certifications and settlement terms must be evaluated separately from the patent text.
- The patent is most commercially relevant to a generic fingolimod label that reproduces the Gilenya initiation and escalation regimen.
FAQs
Does US Patent 8,492,441 cover fingolimod itself?
No. It covers methods of administering S1P receptor agonists. Fingolimod may be covered through dependent claims identifying Compound A, but the patent does not claim the fingolimod molecule as such.
Can a generic sell fingolimod without infringing this patent?
Potentially, but the result depends on the proposed label, dosage instructions, indication and any enforceable patent term. A label that directs low-dose initiation followed by escalation presents the highest risk.
Is the 10-day titration period required by every claim?
No. The 10-day limitation appears in claims 15 and 16. Claims 1 and 9 do not require a 10-day period, and claim 13 requires stepwise escalation without expressly requiring 10 days.
Does claim 8 require exact doubling of the dose?
No. Claim 8 requires that the dose on a particular day equal the sum of the doses on the prior two days within a plus-or-minus 40% range. It is a quantitative escalation limitation, not an absolute doubling requirement.
Could the patent apply to S1P drugs other than fingolimod?
Yes. Claim 1 and claim 9 are not expressly limited to fingolimod. Claim 4 also defines a broader chemical genus. The applicability to another S1P agonist would depend on the drug’s pharmacology, dosing regimen and whether its structure falls within the claimed genus.
References
- United States Patent and Trademark Office. (2013). US Patent No. 8,492,441, Methods of administering S1P receptor agonists.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 and 35 U.S.C. §§ 156, 271, 282.
- U.S. Food and Drug Administration. (2010). Gilenya prescribing information. Novartis Pharmaceuticals Corporation.
